Introduction
============

Atopic dermatitis (eczema) is an itchy inflammatory skin disease that affects ∼10.7% of children in the United States ([@bib36]) and up to 25% in the United Kingdom ([@bib16]; [@bib35]). Atopic dermatitis can cause significant morbidity ([@bib20]) and the associated family stress is a substantial social and financial burden ([@bib41]).

Loss-of-function mutations in the filaggrin gene (*FLG;* OMIM ^\*^135940) cause the dry scaly skin condition ichthyosis vulgaris ([@bib37]) (OMIM \#146700) and are strongly and significantly associated with atopic dermatitis ([@bib26]; [@bib30]; [@bib40]). *FLG* is expressed in terminally differentiating keratinocytes in the outermost layers of the human epidermis as a large, insoluble polyprotein, profilaggrin. Each inactive profilaggrin molecule is dephosphorylated and cleaved into 10, 11, or 12 functional filaggrin monomers ([@bib12]; [@bib33]). Filaggrin plays a key role in epithelial barrier function: it aggregates and aligns keratin bundles in the cornified cell envelope and is further degraded to release hygroscopic amino acids, constituents of the "natural moisturizing factor" in human skin ([@bib28]; [@bib32]).

*FLG* is located within the epidermal differentiation complex on chromosome 1q21, a dense cluster of genes involved in keratinocyte differentiation ([@bib23]). *FLG* belongs to the "fused" S100 gene family, characterized by a repetitive sequence in a large third exon ([@bib32]). The human *FLG* gene is polymorphic, with common allelic variants showing 10, 11, or 12 nearly identical tandem repeats in exon 3, each ∼972 bp in length ([@bib12]; [@bib33]). The *FLG* locus therefore demonstrates intragenic copy number variation, using the definition of copy number variation (CNV) proposed by [@bib29]) and [@bib1]. Each repeat at the DNA level encodes a complete copy of the 324 amino-acid filaggrin polypeptide, the functional protein product of the gene. Alleles encode 10, 11, or 12 copies of the filaggrin monomer, and consequently CNV may affect the quantity of filaggrin expressed in the epidermis.

Early CNV studies, based on BAC (Bacterial Artificial Chromosome) arrays or low-resolution oligonucleotide platforms, were able to identify CNVs \>100 kb ([@bib15]; [@bib34]; [@bib29]; [@bib1]). More recent studies have achieved genome-wide assessment of CNVs above 450--500 bp in length using comparative genomic hybridization ([@bib6]; [@bib7]), but this technique currently lacks the power to study rare alleles or to detect an odds ratio of \<1.4 ([@bib7]). We therefore used detailed PCR-based genotyping strategies to define size variants of exon 3 of *FLG* to investigate whether CNV contributes to the risk of atopic dermatitis.

Results
=======

A case--control study using a total of 925 Irish pediatric atopic dermatitis cases and 998 Irish population controls was used to test the hypothesis that CNV within *FLG* affects atopic dermatitis risk. Of these, 876 cases (94.7%) and 928 controls (93.0%) were successfully genotyped; the demographic and clinical data are summarized in [Table 1](#tbl1){ref-type="table"}.

*FLG* copy number variants in the Irish population
--------------------------------------------------

A total of 100 consecutive atopic dermatitis cases were screened by long-range PCR and there was no evidence of CNV within the 5′ portion of *FLG* exon 3, representing repeats numbered 1 to 7 ([Figures 1](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}). All 925 cases and 998 controls were screened using a separate long-range PCR to identify copy number variation within the 3′ portion of *FLG* exon 3, representing repeats 7 to the end of the repetitive region ([Figures 1](#fig1){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and a TaqMan allelic discrimination assay for single-nucleotide polymorphism (SNP) rs12730241. In the Irish control population, the most prevalent allele size was 11 repeats, representing 51.5% of alleles; the 10-repeat allele frequency was 33.9% and the 12-repeat allele frequency was 14.6%. Allele counts in cases and controls are summarized in [Table 2](#tbl2){ref-type="table"}.

*FLG-*null mutation screening
-----------------------------

All four prevalent *FLG-*null mutations were successfully typed in 855 out of the 876 (97.6%) cases genotyped for copy number and 926 out of 928 (99.8%) controls genotyped for copy number. Of the fully genotyped individuals, 327 (38.2%) of cases and 102 (11.0%) of controls carried one or two *FLG-*null mutations; 528 cases and 824 controls were of wild-type genotype for the four *FLG-*null mutations ([Table 1](#tbl1){ref-type="table"}).

*FLG* copy number affects the risk of atopic dermatitis
-------------------------------------------------------

*FLG-*null mutation carriers were excluded from further analysis to allow independent assessment of the CNV effect. After exclusion of the *FLG-*null mutation carriers, χ^2^ testing showed a significantly higher total copy number in the controls than in the atopic dermatitis cases (*P*=0.043). Furthermore, logistic regression analysis of the total copy number as continuous data (considering 20, 21, 22, 23, and 24 copies) showed that the addition of each subsequent filaggrin-encoding unit reduces the odds ratio of disease by a factor of 0.88 (95% confidence interval 0.78--0.98, *P*=0.025). Therefore, an individual having two 12-repeat alleles, compared with an individual with two 10-repeat alleles, has a risk reduction of 0.88 to the power of 4, meaning a 0.60 times reduced risk of developing atopic dermatitis.

The concentrations of filaggrin breakdown products correlate with *FLG* copy number
-----------------------------------------------------------------------------------

Linear regression analysis comparing filaggrin breakdown products quantified by HPLC of tape-stripped stratum corneum from 31 atopic dermatitis cases ([@bib18]) showed a small but statistically significant correlation between urocanic acid concentration (UCA) and *FLG* total copy number (*r*=0.42, *P*=0.018; [Supplementary Figure S1a](#sup1){ref-type="supplementary-material"} online). The value *r*^2^=0.18 indicates that 18% of the variation of UCA in the stratum corneum samples may be attributed to *FLG* CNV. The concentrations of two other breakdown products of filaggrin, histidine and pyrrolidone-5-carboxylic acid (PCA), each also showed a small positive correlation with *FLG* total copy number (histidine *r*=0.20, PCA *r*=0.28) but these were not statistically significant ([Supplementary Figure S1b and c](#sup1){ref-type="supplementary-material"} online).

Discussion
==========

Assessment of the entire range of genetic and genomic variation (including SNPs, structural variation, noncoding variants, long-range *trans* effects, and so on) will be required in order to fully understand the genetic predisposition to complex traits such as atopic dermatitis. Loss-of-function mutations in *FLG* represent the strongest and most significant genetic factor in the etiology of atopic dermatitis characterized to date ([@bib2]; [@bib30]; [@bib40]), with an odds ratio estimated by meta-analysis to be 3.12 ([@bib2]). This study contributes to the understanding of haploinsufficiency in atopic dermatitis by showing that CNV within *FLG* also significantly affects atopic dermatitis risk. The CNV effect is independent of *FLG-*null mutations but the overall effect size is smaller, as the comparable odds ratio is 1/0.88=1.14. However, logistic regression analysis shows a dose-dependent effect, such that the risk reduces incrementally as the total number of filaggrin monomers encoded on a pair of alleles increases. Therefore, an individual with 20 filaggrin repeats has an odds ratio of 1/0.60=1.67 compared with an individual having a total of 24 repeats. As all of the size variant alleles are common within the population (33.9%, 10 repeats; 51.5%, 11 repeats; and 14.6%, 12 repeats), this form of genetic variation represents a significant additional contribution to AD risk.

The polymorphic *FLG* alleles segregate in families according to Mendelian inheritance ([@bib12]) and therefore may contribute to the observed familial clustering of atopic disease ([@bib3]). Filaggrin is a histidine-rich protein ([@bib21]) and *FLG-*null mutations have been shown to affect the quantitative expression of histidine and subsequent filaggrin breakdown products in the stratum corneum of atopic dermatitis patients and control individuals ([@bib17], [@bib18]). This study has shown that CNV within *FLG* may have a significant functional effect on the amount of UCA in the stratum corneum, with a small but significant correlation accounting for ∼18% of the variation in UCA concentration. UCA is a component of the "natural moisturizing factor" in the epidermis ([@bib28]) and plays a role in the maintenance of stratum corneum hydration as well as being a putative UV photoprotector ([@bib9]). The quantitative data linking *FLG* CNV with stratum corneum UCA concentration therefore provide support for the observed genetic epidemiological association. The other filaggrin breakdown products, histidine and PCA, also showed a small positive correlation with filaggrin copy number; however, a larger study is required in order to confirm or refute these correlations.

Two dermatological disorders have so far been shown to exhibit CNV as a mechanism contributing to their pathogenesis: microdeletions on chromosome 17q24.2--q24.3 in congenital generalized hypertrichosis terminalis with or without gingival hyperplasia ([@bib38]); and deletions of the late cornified cell envelope genes *LCE3B* and *LCE3C* in psoriasis ([@bib8]; [@bib14]). The extent to which CNV contributes to the "missing heritability" of common complex traits, including psoriasis and atopic dermatitis, remains to be defined. The three common *FLG* allele sizes (10, 11, and 12) have previously been reported in American and Irish populations ([@bib12]; [@bib13]; [@bib33]). [@bib12]) screened over 300 individuals by Southern blot and showed that there were approximately equal proportions of 10-, 11-, and 12-repeat alleles. In our much larger study of the Irish population, roughly one-third of alleles have 10 repeats, half have 11 repeats, and the remaining 15% are 12-repeat alleles. An investigation of 113 individuals from Winnipeg Canada suggested that the 12-repeat allele may be a protective factor against self-perceived frequent dry skin ([@bib13]), but this study was performed before knowledge of *FLG-*null mutations as a cause of common ichthyosis ([@bib26]; [@bib4]), and hence the data are difficult to interpret. In retrospect, it appears likely that the observed association is attributable to a risk effect of the two common, ancestral *FLG-*null mutations (R501X and 2282del4) that usually do not occur on the 12-repeat allele (A Sandilands, unpublished data).

It is theoretically possible that the observed association of copy number with atopic dermatitis risk may be caused by linkage of the 10-repeat allele to an unrecognized *FLG* loss-of-function mutation. However, this is unlikely to account for the statistically significant association for three reasons: the prevalence and distribution of *FLG-*null mutations in the Irish population is well established ([@bib33]) and mutations other than the four that were assayed in this study are rare; furthermore, the statistical analysis of the continuous data shows an incremental reduction in the risk of atopic dermatitis with each additional unit of copy number; finally, the correlation of total copy number with stratum corneum UCA concentration provides additional evidence of a stepwise functional effect.

Carriers of the four *FLG-*null mutations that are prevalent in the population were excluded from statistical analysis in order to study the independent effect of CNV on atopic dermatitis risk. This approach is necessary because *FLG-*null mutations have such a profound effect on filaggrin expression, which is reduced to near zero in homozygotes or compound heterozygotes ([@bib33]), that the more subtle effect of CNV could be obscured. It would be interesting to study the effect of CNV *in trans* with *FLG-*null mutations to investigate the possibility that larger copy number variants may provide some protection by partially ameliorating the effect of a *FLG-*null allele, or conversely the smaller copy number variants may serve to worsen the phenotype of a *FLG*-null heterozygote. However, even the total sample size of nearly 2,000 individuals in this study was not large enough to have sufficient power to permit such haplotype analysis. It would also be interesting to investigate the effect of *FLG* CNV on atopic dermatitis severity, with the hypothesis that a greater number of repeats protects against severe disease whereas a smaller number of repeats increases the risk of severe disease. However, this study, having predominantly moderate--severe atopic dermatitis cases, did not have sufficient statistical power to draw any firm conclusions regarding the effect of copy number on disease severity.

Previously published whole-genome association studies of CNVs focused on eight common complex traits of importance to human health ([@bib7]); a separate study characterized CNVs of \>443 bp in 450 individuals as reference genotypes from European, East Asian, and African individuals ([@bib6]). The careful and rather laborious genotyping strategy utilized for this study has given detailed information on size variation within exon 3 of *FLG* in nearly 2,000 Irish individuals and the same three size variants---encoding 10, 11, and 12 copies of the filaggrin monomer---have been identified. Rarer size variants including duplications, a 3.7-kb deletion ([@bib22]), and two large inversions involving the *FLG* locus ([@bib19]; [@bib27]) are recorded as single cases in the UCSC (University of California, Santa Cruz) database. Large inversions and other structural variants may not have been detected using our PCR-based genotyping assays and these cases may have contributed to the 5.3% of cases and 7.0% of controls in whom CNV genotyping failed. In contrast to human *FLG*, mouse strains show a wide range of CNV within the orthologous murine gene (*flg*), where characterized strains show between 10 and 20 filaggrin subunits ([@bib43]). Although this study focused on CNV of 972 bp sequences within *FLG* exon 3, it is clearly possible that larger duplications of the whole *FLG* third exon or indeed the entire *FLG* gene may occur. In light of the dose-dependent effect of intragenic CNV, these larger CNVs would be expected to have an even greater effect on filaggrin "dose" in the epidermis and warrant further investigation.

The discovery that *FLG-*null mutations are a strong and significant risk factor for atopic dermatitis has already led to a greater understanding of the importance of skin barrier function in atopic disease ([@bib32]). The fact that CNV within *FLG* significantly affects atopic dermatitis risk raises the attractive possibility that treatments aimed at increasing filaggrin expression may have a therapeutic effect on the prevention and/or treatment of atopic dermatitis. Encouragingly, our data show that even a 5--10% increase in filaggrin "dose" results in a significant reduction in the incidence of atopic dermatitis. Furthermore, as this analysis excluded *FLG-*null mutation carriers, the benefit is not likely to be restricted to the ∼10% of individuals in the population who carry a *FLG-*null mutation ([@bib37]; [@bib31]). It is perhaps surprising to observe that a 5--10% increase in filaggrin copy number is sufficient to result in a reduced risk of atopic dermatitis. There is likely to be considerable inter- and intra-individual variation in the rates of biosynthesis, processing, and degradation of filaggrin, but it may be speculated that the life-long effect of a genetically determined 5--10% increase in filaggrin "dose" may provide sufficient enhancement to skin barrier function to result in the observed risk reduction. Feasibility studies are currently underway in the United Kingdom and United States ([@bib11]; [@bib39]) in preparation for a prospective clinical trial to investigate whether intensive emollient application in early life, with the aim of improving skin barrier function, may reduce the risk of atopic dermatitis in infancy. In the future, it may also be possible to target pathways that control filaggrin expression with small molecules and thereby develop therapeutics to boost filaggrin expression in the epidermis. It is hoped that these combined investigations will demonstrate the translation of functional genomics to better care for atopic dermatitis patients in the foreseeable future.

Materials and Methods
=====================

Atopic dermatitis cases
-----------------------

A collection of 925 unrelated Irish pediatric atopic dermatitis cases was recruited through a tertiary referral dermatology clinic at one center, Our Lady\'s Children\'s Hospital, Crumlin, Dublin. Atopic dermatitis was defined according to the UK diagnostic criteria ([@bib42]) and all cases were confirmed on examination by an experienced dermatologist. In all, 51.2% of cases had severe disease; 32.6% had moderate, and 16.2% had mild atopic dermatitis, defined according to the Nottingham Eczema Severity Score ([@bib10]). Demographic and clinical data are summarized in [Table 1](#tbl1){ref-type="table"}. Carriers of the four *FLG-*null mutations that are prevalent in the Irish population (R501X, 2282del4, S3247X, and R2447X) were excluded from subsequent statistical analysis in order to study the independent effect of CNV on atopic dermatitis risk. The genetic architecture of *FLG* loss-of-function mutations has been extensively characterized in the Irish population ([@bib33]; [@bib5]), and together these four mutations account for \>95% of *FLG* mutations; the remaining \<5% are composed of rare and family-specific mutations.

Control population
------------------

A total of 998 control DNA samples were obtained from the Trinity College Dublin Biobank, representing an unselected Irish population, as described previously ([@bib24]). Demographic data relating to the control population are summarized in [Table 1](#tbl1){ref-type="table"}. As with the case collection, carriers of the four prevalent *FLG-*null mutations in the control population were excluded from subsequent statistical analysis.

Ethical considerations
----------------------

This study was conducted with the approval of the local research ethics committee (Our Lady\'s Children\'s Hospital, Crumlin). A parent or guardian for each case and all control subjects gave written informed consent. The collection of DNA samples and clinical data were conducted in accordance with the Good Clinical Practice and the Declaration of Helsinki Principles.

Genotyping strategy
-------------------

The four *FLG* loss-of-function mutations that are most prevalent in the Irish population (R501X, 2282del4, S3247X, and R2447X) were screened in the cases and controls as previously described ([@bib33]; [@bib25]). Copy number variants were distinguished by their different sized products following PCR amplification. Amplification of the whole of exon 3 results in rather large products, ranging from 12,413 to 14,357 base pairs, within which size variants are difficult to distinguish reliably with the necessary resolution of 1,000 base pairs. Long-range PCR reactions were therefore designed to amplify the region of interest in two partially overlapping portions ([Figure 1](#fig1){ref-type="fig"}) as follows. In the first PCR reaction (PCR 1), the 5′ portion of *FLG* exon 3, from intron 2 (at a point near exon 3) to repeat 7, was amplified by long-range PCR using primers listed in [Table 3](#tbl3){ref-type="table"}. PCR reactions (50 μl) were performed using the TaKaRa LA Taq (Takara Bio, Shiga, Japan) with 200 ng genomic DNA, 1 unit of TaKaRa LA Taq, 8 μl dNTPs (2.5 m each), 25 ng each of the forward and reverse primers, 5 μl 10 × Buffer (TaKaRa), and 5 μl MgCl (25 m). Cycle conditions for PCR 1 were as follows: 94 °C initial denaturation for 1 minute, followed by 33 cycles of denaturation (94 °C for 30 seconds) and elongation (68 °C for 10 minutes), followed by a final elongation at 72 °C for 10 minutes. Electrophoresis on a 0.8% w/v agarose gel, at 120 V for 3 hours, was used to identify product size. In a second PCR reaction (PCR 2), the 3′ portion of *FLG* exon 3, encompassing repeats 7 to 10 plus the 3′ partial repeat, was amplified by long-range PCR using the primers shown in [Table 3](#tbl3){ref-type="table"}. Reactions (20 μl) were performed using the Expand High Fidelity System (Roche Applied Science, Mannheim, Germany) with ∼100 ng genomic DNA, 1.5 units of Expand High Fidelity enzyme, 2 μl dNTPs (2.5 m each), 10 ng each of the forward and reverse primers, 2 μl Buffer 2 (Roche Expand High Fidelity System), and 4% v/v DMSO. Cycle conditions for PCR 2 were as follows: 95 °C initial denaturation for 5 minutes, followed by 35 cycles of denaturation (94 °C for 30 seconds), annealing (63.5 °C for 30 seconds) and elongation (72 °C for 5 minutes 30 seconds), followed by a final elongation at 72 °C for 7 minutes. Products were separated as for PCR 1, on a 0.8% w/v agarose gel.

The largest product from PCR 2 is most at risk of suboptimal amplification, resulting in a weaker band when visualized on a gel under UV light. In order to minimize the risk of failing to detect the largest size allele, an additional SNP genotyping strategy was used. SNP rs12730241 is in the 3′ untranslated region of *FLG* (near to the duplicated repeats) and was shown, in 89 out of 90 (98.9%) fully sequenced individuals, to be associated with the 12-repeat allele. Rs12730241 was typed using the available predesigned TaqMan allelic discrimination assays (Applied Biosystems, Foster City, CA) according to the manufacturer\'s recommended protocols. Therefore, 12-repeat alleles shown by long-range PCR were confirmed by genotyping for SNP rs12730241.

Quantification of filaggrin breakdown products
----------------------------------------------

Data relating to the most abundant filaggrin breakdown products---histidine, UCA, and PCA---in 31 *FLG* wild-type atopic dermatitis cases were available from a previous study ([@bib18]). Stratum corneum samples removed from the nonlesional skin of pediatric atopic dermatitis cases by a tape-stripping technique had undergone HPLC to quantify histidine, UCA, and PCA as previously described ([@bib18]).

Statistical analysis
--------------------

In individuals with a wild-type genotype at the four screened *FLG-*null mutations, total copy number was defined as the sum of the number of tandem repeats on each allele. Total copy number genotype frequencies were compared between the case and control groups using χ^2^ test and logistic regression analysis, performed with the statistical analysis package Stata (StataCorp LP, College Station, TX). Simple linear regression was used to test for correlation between total copy number and *FLG* breakdown products using SPSS v 15.0.1 (IBM Corporation, Somers, NY).
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![***Filaggrin* (*FLG*) structure and genotyping strategies to identify copy number variants.** LD, linkage disequilibrium; SNP, single-nucleotide polymorphism. Diagram adapted from [@bib37]). ](jid2011342f1){#fig1}

![**Visualization of PCR 1 products showing no evidence of copy number variation (CNV) within the 5′ portion of *filaggrin* (*FLG*) exon 3.** PCR reactions separated on 0.8% agarose gel. Bioline hyperladder I marker (Bioline, London, UK).](jid2011342f2){#fig2}

![**Visualization of PCR 2 products showing product sizes representing 10-, 11-, and 12-repeat alleles from the 3′ portion of *filaggrin* (*FLG)* exon 3.** PCR reactions separated on 0.8% agarose gel. Bioline hyperladder I marker (Bioline).](jid2011342f3){#fig3}

###### Demographic and clinical data relating to atopic dermatitis cases and unselected population controls

                                                **Irish pediatric atopic dermatitis cases**   **Irish population controls**                 
  --------------------------------------------- --------------------------------------------- ------------------------------- ------------- -------------
  Male sex, number (%)                          545 (62.2)                                    332 (62.9)                      278 (30.0)    251 (30.5)
  Mean age, years (SD)                          3.3 (3.5)                                     3.0 (3.3)                       36.2 (12.4)   36.2 (12.5)
  Nottingham eczema severity score, mean (SD)   11.2 (2.6)                                    11.0 (2.5)                      Not known     Not known

The diagnosis of atopic dermatitis was made by experienced dermatologists according to the United Kingdom diagnostic criteria ([@bib42]) with disease severity scored according to the Nottingham Eczema Severity Score, in which 1 to 8 denotes mild atopic dermatitis, 9 to 11 is moderate, and 12 to 15 defines severe disease ([@bib10]). The control population represents consecutive successfully genotyped Trinity Biobank Control samples, derived from Irish adult blood donors.

###### *FLG* genotypes, null mutations, and copy number variants in 876 Irish atopic dermatitis cases and 928 Irish population controls

                        **Whole collection**   ***FLG* mutation carriers excluded**                
  --------------------- ---------------------- -------------------------------------- ------------ ------------
  10 Repeats            696 (39.7)             629 (33.9)                             410 (38.8)   550 (33.4)
  11 Repeats            814 (46.5)             956 (51.5)                             497 (47.1)   856 (51.9)
  12 Repeats            242 (13.8)             271 (14.6)                             149 (14.1)   242 (14.7)
                                                                                                    
  *Total copy number*                                                                               
  20                    NA                     NA                                     85 (16.1)    87 (10.6)
  21                    NA                     NA                                     186 (35.2)   300 (36.4)
  22                    NA                     NA                                     172 (32.6)   294 (35.7)
  23                    NA                     NA                                     75 (14.2)    120 (14.6)
  24                    NA                     NA                                     10 (1.9)     23 (2.8)
  χ^2^ test                                                                           *P*=0.043    
  Logistic regression                                                                 *P*=0.025    

Abbreviations: *FLG*, *filaggrin*; NA, not applicable.

Total copy number denotes the sum of the number of repeats on each allele in an individual showing *FLG* wild-type genotype at the four prevalent null mutations. The *FLG* and copy number allelic variants each did not show a significant deviation from Hardy--Weinberg equilibrium (*P*\>0.05) in the control population.

###### PCR primers for amplification of *FLG* exon 3

  **PCR reaction**                                           **Forward primer sequence**    **Reverse primer sequence**   **Product sizes (bp)**
  ---------------------------------------------------------- ------------------------------ ----------------------------- -------------------------
  Amplification of beginning of exon 3 to repeat 7 (PCR 1)   5′-GCTGATAATGTGATTCTGTCTG-3′   5′-CTGGCTAAAACTGGATCCCCA-3′   7,624
  Amplification of repeat 7 to 3′ partial repeat (PCR 2)     5′-CCCAGGACAAGCAGGAACT-3′      5′-CTGCACTACCATAGCTGCC-3′     4,277, 5,249, and 6,224

Abbreviations: bp, base pairs; *FLG*, *filaggrin*.
